引用次数
引用: 40,448
H-指数: 103
I10-指数 : 362
出版物: 597
Leukemia cell line inhibition of cell proliferation, autophosphorylation, kinase activity, and induction of apoptosis by tyrphostin AG1112 and AG957.
KD Cheng , R Kurzrock , Z Estrov , A Levitzki
Blood 88 ( 10) 3512 -3512
1
1996
Novel tyrphostin analogues inhibit Stat3 activation and induce apoptosis in multiple hematological malignancies.
LY Kong , M Talpaz , W Priebe , A Levitzki
Blood 102 ( 11) 204B -204B
3
2003
The protein kinase inhibitor AG1801 abrogates constitutive STAT3 phosphorylation, suppresses colony-forming cell proliferation, and activates the apoptotic pathway in chronic lymphocytic leukemia (CLL).
A Ferrajoli , MJ Keating , Q Van , DM Harris
Blood 102 ( 11) 231A -231A
1
2003
Correction: EGF Receptor-Targeted Synthetic Double
A Shir , M Ogris , E Wagner , A Levitzki
2007
The tyrphostin AG494 reduces IL2-induced activation of Jak3 and inhibits proliferation of human leukemia cells
R Mandler , A Levitzki , AJ Roettinger , A Gazit
EUROPEAN CYTOKINE NETWORK 9 ( 3) 401 -401
1998
Stent-based tyrphostin AGL-2043 reduces neointima formation in porcine coronary arteries
S Banai , G Golomb , L Gavish , M Chorny
CIRCULATION 110 ( 17) 121 -121
2004
Selective pdgf receptor protein tyrosine kinase blocker inhibits smooth muscle cell outgrowth from porcine arterial tissue and human atheroma
A Pearle , SD Gertz , Y Wolf , G Golomb
CIRCULATION 94 ( 8) 3062 -3062
1996
Signal therapy of RAS cancers by blocking PAK pathways
M Hiroshi , H Maruta , H He , Y Hirokawa
EUROPEAN JOURNAL OF CANCER 38 S93 -S93
2002
Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.
JC LopezTalavera , A Levitzki , M Martínez , R Esteban
HEPATOLOGY 24 ( 4) 755 -755
1996
Session A: Conjoint Day SUNDAY-A-10-Fluorinated EGFR-TK inhibitor-based tracers for PET
E Mishani , T Bonasera , Y Rozen , G Ortu
Journal of Labelled Compounds and Radiopharmaceuticals 42 ( 1) S27 -S27
17
1999
Hormone and antihormone action at the target cell
James H Clark , W Klee , A Levitzki , J Wolff
Dahlem Konferenzen, Berlin 29 -38
17
1976
Ligand binding
A Levitzki
Protein function: a practical approach 101 -129
12
1997
Curr. Topics in Cell
A Levitzki , DE Koshland
Regulation 10 2 -38
10
1976
Dual control of adenylate cyclase
A Levitzki
G-Proteins as Mediators of Cellular Signalling Processes. Wiley, Chichester, UK 1 -14
9
1990
Tyrphostins inhibit PDGF induced DNA synthesis, tyrosine specific protein kinase activity and c-fos mRNA expression in vascular smooth muscle cells
G Bilder , JA Krawiec , A Gazit , C Gilon
Am J Physiol 260 C721 -C730
8
1991
Protein tyrosine kinase inhibitors
A Levitzki
New Molecular Targets for Cancer Chemotherapy 67 -79
5
1994
Novel EGFR irreversible tyrosine kinase inhibitor candidates for the diagnostic and therapeutic treatment of cancer
E Mishani , G Abourbeh , G Ortu , Y Rozen
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS 46 S115 -S115
4
2003
The selectivity of small molecules towards protein tyrosine kinases
A Levitzki
Data Mining in Structural Biology: Signal Transduction and Beyond 71 -80
4
2001
SUBUNIT STRUCTURE AND INTERACTIONS OF CTP SYNTHETASE
CW Long , A Levitzki , LL Houston , KOSHLAND. DE
FEDERATION PROCEEDINGS 28 ( 2) 342 -&
4
1969
Carbon-11 Labeling of 4-Dimethylamino-But-2-Enoic Acid [4-(phenylamino)-quinazolin-6-yl]-Amides, a New Class of EGFR Irreversible Inhibitors
E Mishani , G Abourbeh , Y Rozen , D Laki
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS 46 S2 -S2
3
2003